Clinical Trial
NCT02686658 Completed
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Disease
Disease type
Geographic Atrophy
Orphan drug recognition
Yes
Patient type
Adult
Children
Inclusion / Exclusion
Funding
private
Members involved
Others investigators
Dr Artur Klett
Representative
Estonia
Anterior Segment Rare Eye Diseases (WG4), National Integration (TWG9)
Dr Kristel Harak
Estonia
Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Registries & Epidemiology (TWG7), Retinal Rare Eye Diseases (WG1)
ERN EYE member investigating site
HCP : Principal investigators
East-Tallinn Central Hospital Eye Clinic, Tallinn, Estonia
Adress
Ravi 18
10138 Tallinn
Estonia
Klinikum der Universität München, Germany
Adress
Mathildenstraße 8
80336 Munich
Germany